| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 6,783 | 3,820 | 3,016 | 3,860 |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 2,846 | 1,710 | 1,507 | 1,526 |
| Gross profit | 3,937 | 2,110 | 1,509 | 2,334 |
| General and administrative | 7,884 | 6,409 | 4,892 | 4,487 |
| Sales and marketing | 403 | 260 | 358 | 346 |
| Depreciation and amortization | 384 | 306 | 177 | 146 |
| Total operating expenses | 8,671 | 6,975 | 5,427 | 4,979 |
| Operating loss | -4,734 | -4,865 | -3,918 | -2,645 |
| Other expense | -679 | -163 | -4 | -18 |
| Other income | 13 | 15 | 58 | 47 |
| Loss before income taxes | -5,400 | -5,013 | -3,864 | -2,616 |
| Net loss | -5,400 | -5,013 | -3,864 | -2,616 |
| Net loss per share (basic) | -0.49 | -0.55 | -0.45 | -0.4 |
| Net loss per share (diluted) | -0.49 | -0.55 | -0.45 | -0.4 |
| Weighted average number of shares of common stock outstanding (basic) | 10,963,590 | 9,087,202 | 8,595,288 | 6,615,320 |
| Weighted average number of shares of common stock outstanding (diluted) | 10,963,590 | 9,087,202 | 8,595,288 | 6,615,320 |
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)